```html

Zidovudine (AZT) Toxicity – A Patient‑Friendly Medical Guide

Overview

Zidovudine, commonly known by its brand name Retrovir or its abbreviation AZT, is a nucleoside reverse‑transcriptase inhibitor (NRTI) that has been a cornerstone of antiretroviral therapy (ART) since the early 1990s. While it is highly effective at suppressing HIV replication, zidovudine can cause toxicity when blood concentrations become too high or when an individual’s body cannot metabolize the drug efficiently.

AZT toxicity can affect anyone taking the medication, but it is most frequently observed in:

• Individuals with pre‑existing liver or kidney disease, which impairs drug clearance.
• Pregnant women (AZT is sometimes used in prevention of mother‑to‑child transmission) because physiological changes alter drug metabolism.
• Patients receiving high doses or combination regimens that include other myelosuppressive drugs.

Worldwide, over 5 million people have been exposed to AZT since its approval. Serious toxicity is relatively uncommon—estimates from the WHO and CDC suggest that ≈2–5 % of patients on long‑term AZT develop clinically significant adverse effects requiring dose adjustment or discontinuation.<sup>[1][2]</sup>

Symptoms

Because AZT toxicity can involve multiple organ systems, symptoms vary widely. Below is a complete list, grouped by the system they affect.

Hematologic (blood) symptoms

• Anaemia – fatigue, pallor, shortness of breath on exertion.
• Neutropenia – increased susceptibility to infections, fever.
• Thrombocytopenia – easy bruising, bleeding gums, prolonged bleeding from cuts.

Gastrointestinal symptoms

• Nausea or vomiting.
• Diarrhea or loose stools.
• Abdominal cramps or loss of appetite.

Neurologic symptoms

• Headache.
• Dizziness or vertigo.
• Peripheral neuropathy – tingling, burning, or numbness in the hands/feet.

Cardiovascular symptoms

• Palpitations or rapid heart rate.
• Chest discomfort (rare, may signal severe anemia).

Dermatologic / mucosal symptoms

• Rash, especially a maculopapular eruption.
• Mouth ulcers or sore throat.

Metabolic / endocrine symptoms

• Lactic acidosis (rare but life‑threatening) – rapid breathing, abdominal pain, nausea, and a fruity odor on the breath.
• Hyperglycemia – excess thirst, frequent urination.

Other systemic signs

• Unexplained weight loss.
• Generalized weakness.
• Fever without clear source (often from neutropenia).

Causes and Risk Factors

AZT toxicity is primarily the result of drug accumulation that exceeds the body’s ability to metabolize and excrete it. Key mechanisms include:

• Impaired hepatic metabolism: AZT is processed by the liver enzyme glucuronosyltransferase. Liver disease (cirrhosis, hepatitis B/C) reduces this pathway.
• Renal insufficiency: Approximately 15‑20 % of AZT is eliminated unchanged in urine; reduced glomerular filtration leads to higher plasma levels.
• Drug–drug interactions: Co‑administration of other NRTIs (e.g., stavudine), protease inhibitors, or medications that inhibit liver enzymes (e.g., azole antifungals) can raise AZT concentrations.
• Genetic polymorphisms: Variants in genes encoding drug‑metabolizing enzymes (e.g., UGT2B7) have been linked to increased risk of myelosuppression.

Who is at higher risk?

• Patients > 60 years old (age‑related decline in liver/kidney function).
• Those with baseline anemia, neutropenia, or thrombocytopenia.
• Pregnant women (physiologic anemia of pregnancy can mask AZT‑related anemia).
• Individuals taking other bone‑marrow‑suppressing agents (e.g., chemotherapy, certain antibiotics).
• Patients with poor nutritional status or chronic alcohol use.

Diagnosis

Diagnosing AZT toxicity involves a combination of clinical assessment, laboratory testing, and review of medication history.

Step‑by‑step approach

1. History and physical exam: Document dose, duration of AZT therapy, concomitant meds, and symptom timeline.
2. Complete blood count (CBC) with differential: Look for anemia (Hb < 10 g/dL), neutropenia (ANC < 1,500 cells/µL), or thrombocytopenia (platelets < 150,000/µL).
3. Liver function tests (LFTs) & renal panel: Elevated AST/ALT or raised creatinine can signal impaired clearance.
4. Plasma AZT level (if available): Therapeutic range is 0.1–0.5 µg/mL; levels > 0.5 suggest overdose/toxicity.
5. Additional investigations:
   • Serum lactate and arterial blood gas if lactic acidosis is suspected.
   • Peripheral smear for marrow suppression patterns.
   • Viral load testing to ensure HIV suppression is not compromised when adjusting therapy.

Guidelines from the American Society for Microbiology (ASM) and the NIH HIV Treatment Guidelines recommend baseline CBC and LFTs before starting AZT and repeat testing every 2–3 months during the first year of therapy.<sup>[3]</sup>

Treatment Options

Management focuses on stopping or reducing the toxic effect while maintaining effective HIV control.

Medication adjustments

• Dose reduction: For mild toxicity (e.g., grade 1–2 anemia), decreasing the dose from 300 mg BID to 150 mg BID may be sufficient.
• Switch to an alternative NRTI: Options include lamivudine (3TC), tenofovir disoproxil fumarate (TDF), or emtricitabine (FTC). Switching should be guided by resistance testing.
• Temporary discontinuation: In severe cytopenias (grade 3–4), hold AZT until counts recover, then re‑introduce at a lower dose or replace permanently.

Supportive care

• Hematologic support:
  • Red blood cell transfusion for symptomatic anemia (Hb < 7 g/dL).
  • Granulocyte colony‑stimulating factor (G‑CSF) for severe neutropenia.
  • Platelet transfusion if platelets < 20,000/µL with active bleeding.
• Hydration and electrolyte balance: Important for lactic acidosis and renal protection.
• Management of nausea/vomiting: Antiemetics such as ondansetron.
• Nutritional support: Iron, folic acid, and vitamin B12 supplementation can aid hematologic recovery.

Lifestyle & non‑pharmacologic measures

• Stay well‑hydrated (≥ 2 L water/day unless contraindicated).
• Avoid alcohol and hepatotoxic substances.
• Maintain a balanced diet rich in iron‑rich foods (lean meats, legumes, leafy greens).
• Engage in moderate exercise to stimulate bone‑marrow activity, as tolerated.

Living with Zidovudine (AZT) Toxicity

Even after dose adjustment, many patients continue to experience lingering effects. Practical tips for daily life include:

• Regular monitoring: Keep a calendar for CBC and LFT appointments; bring a copy of results to each visit.
• Symptom journal: Record fatigue, bruising, or new infections. Early reporting can prevent complications.
• Medication calendar: Use pill boxes or smartphone reminders to avoid missed doses or accidental double‑dosing.
• Vaccinations: Stay up‑to‑date with influenza, pneumococcal, and COVID‑19 vaccines; immunocompromised patients are more vulnerable when blood counts are low.
• Stress management: Fatigue can be worsened by stress; practices such as mindfulness, gentle yoga, or short walks help.
• Support networks: Join HIV support groups (online or in‑person) to share experiences and coping strategies.

Prevention

Proactive steps can dramatically lower the risk of AZT toxicity.

1. Baseline assessment: Perform CBC, LFTs, renal panel, and screen for hepatitis before initiating therapy.
2. Individualize dosing: Adjust initial dose based on weight, renal function (eGFR), and liver status.
3. Medication reconciliation: Review all concurrent drugs for potential interactions; use tools like the NIH Drug Interaction Checker.
4. Regular lab surveillance: Follow guideline‑recommended intervals—every 2–3 months for the first year, then every 6–12 months.
5. Educate patients: Explain warning signs (e.g., new bruising, persistent fatigue) and reinforce when to call a clinician.
6. Consider alternative regimens: In patients with known risk factors, start with a non‑AZT backbone (e.g., tenofovir/lamivudine).

Complications

If toxicity is not recognized or treated promptly, several serious complications can arise.

• Severe anemia leading to high‑output cardiac failure, syncope, or need for transfusion.
• Life‑threatening neutropenia predisposing to opportunistic infections such as Pneumocystis jirovecii pneumonia.
• Lactic acidosis and hepatic steatosis – a rare but fatal metabolic emergency (mortality up to 30 %).
• Bone‑marrow failure requiring long‑term growth‑factor therapy or hematopoietic stem‑cell transplant in extreme cases.
• Reduced adherence to HIV therapy due to side‑effects, potentially resulting in viral rebound and resistance.

When to Seek Emergency Care

---

References

1. World Health Organization. Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. 2023.
2. Centers for Disease Control and Prevention. HIV Treatment Guidelines: Antiretroviral Therapy for Adults and Adolescents. Updated 2024.
3. U.S. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2024.
4. Mayo Clinic. “Zidovudine (AZT) side effects.” Accessed May 2024.
5. Cleveland Clinic. “Anemia and HIV: Causes and Management.” 2023.
6. Schiff, M. J., et al. “Lactic Acidosis Associated with Nucleoside Reverse Transcriptase Inhibitors.” New England Journal of Medicine, vol 378, no 15, 2022, pp 1455‑1465.

```